Targeting tumor stromal cells through a PDGF-beta receptor binding carrier

Jai Prakash; Edwin de Jong; Eduard Post; Ara K. Mohammad; Leonie Beljaars; Klaas Poelstra

doi:10.1016/j.jconrel.2010.07.088

Targeting tumor stromal cells through a PDGF-beta receptor binding carrier

Jai Prakash^*, Edwin de Jong, Eduard Post, Ara K. Mohammad, Leonie Beljaars, Klaas Poelstra

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

3 Downloads (Pure)

Abstract

Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.

Original language	English
Pages (from-to)	e116
Journal	Journal of controlled release : official journal of the Controlled Release Society
Volume	148
Issue number	1
DOIs	https://doi.org/10.1016/j.jconrel.2010.07.088
Publication status	Published - 20 Nov 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jconrel.2010.07.088

Cite this

@article{46995b6b39554bcea6ab7bb41cd72dbb,

title = "Targeting tumor stromal cells through a PDGF-beta receptor binding carrier",

abstract = "Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.",

author = "Jai Prakash and {de Jong}, Edwin and Eduard Post and Mohammad, {Ara K.} and Leonie Beljaars and Klaas Poelstra",

year = "2010",

month = nov,

day = "20",

doi = "10.1016/j.jconrel.2010.07.088",

language = "English",

volume = "148",

pages = "e116",

journal = "Journal of controlled release : official journal of the Controlled Release Society",

issn = "0168-3659",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Targeting tumor stromal cells through a PDGF-beta receptor binding carrier

AU - Prakash, Jai

AU - de Jong, Edwin

AU - Post, Eduard

AU - Mohammad, Ara K.

AU - Beljaars, Leonie

AU - Poelstra, Klaas

PY - 2010/11/20

Y1 - 2010/11/20

N2 - Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.

AB - Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.

UR - http://www.scopus.com/inward/record.url?scp=80052164636&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2010.07.088

DO - 10.1016/j.jconrel.2010.07.088

M3 - Article

C2 - 21529587

AN - SCOPUS:80052164636

SN - 0168-3659

VL - 148

SP - e116

JO - Journal of controlled release : official journal of the Controlled Release Society

JF - Journal of controlled release : official journal of the Controlled Release Society

IS - 1

ER -

Targeting tumor stromal cells through a PDGF-beta receptor binding carrier

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this